trending Market Intelligence /marketintelligence/en/news-insights/trending/7ktSoCNjqACKerQyCYiweg2 content esgSubNav
In This List

Cancer Genetics closes common stock offering

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Cancer Genetics closes common stock offering

Cancer Genetics Inc. closed an underwritten public offering of 13,333,334 common shares at 22.5 cents each.

The company raised gross proceeds of $3 million.

Net proceeds will be used to pay costs related to potential forbearance agreements Cancer Genetics is negotiating with its banks, as well as costs related to on-going strategic initiatives. Remaining funds, if any, will go toward working capital and other general corporate purposes.

Underwriters were granted a 45-day option to buy 2 million additional shares, also at 22.5 cents each.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

Rutherford, N.J.-based Cancer Genetics develops, commercializes and provides molecular and biomarker-based tests and services.